Andreana N. Holowatyj, PhD, MS, Details the Main Results of Research into Colorectal Cancer Disparities

Video

The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.

In a conversation with CancerNetwork®, Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke about the main takeaways from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on tumor mutation burden by race and disparities in early-onset colorectal cancer.

Transcription:

One of the things that we undertook in our analysis was to explore potential differences in tumor mutation burden by race within the population of early-onset colorectal cancer cases. And what we observed in doing so was that compared with young non-Hispanic Whites with a microsatellite stable colorectal tumor, we saw that young non-Hispanic Blacks actually had a significantly higher tumor mutation burden. However, when compared again with [non-Hispanic] Whites, there was no difference in tumor mutation burden with Asian or Pacific Islanders diagnosed with early-onset disease. Seeing this significantly higher tumor mutation burden in young [non-Hispanic] Blacks was quite striking and warranted further study.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content